UroStream

Prostate cancer is the most common malignancy of the male genitourinary system. Compared to Western countries, a larger proportion of prostate cancer patients in China are diagnosed at intermediate to advanced stages, leading to poorer prognosis. At the recent 2024 Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association (CUDA), Urology Frontier invited Dr. Sujun Han from the National Cancer Center/Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, to discuss the background of the development of single-disease quality control indicators for prostate cancer, the value of promoting standardized diagnosis and treatment, and treatment strategies for advanced patients, with the goal of improving both survival rates and quality of life for prostate cancer patients.

In the journey toward a "Healthy China," urology leads the way. From August 9th to 11th, 2024, the eagerly anticipated 2024 Annual Meeting of the Urology Physicians Branch of the Chinese Medical Doctor Association was grandly held in Xi'an. With a broad global perspective, the conference showcased the latest achievements in the field of urology from multiple angles, paving the way for a new chapter in China's healthcare construction alongside urology professionals nationwide. After the event, Urology Frontier had the honor of interviewing the conference chairman, Dr. Nianzeng Xing, Vice President of the Cancer Hospital , Chinese Academy of Medical Sciences and Peking Union Medical College, who shared insights on the conference highlights, Chinese initiatives, and the training of young professionals.